Skip to main content

Table 1 Descriptive statistics for signalment and demographics of dogs enrolled on Day 0 as veterinary patients and included in the effectiveness evaluable population

From: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Demographics of study dogs

European nematode field study

IP: Credelio Plus (n = 278)

CP: Afoxolaner + MO (n = 117)

Purebred, n (%)

160 (57.6)

60 (51.3)

Mixed breed, n (%)

118 (42.4)

57 (48.7)

Age, mean (months)

58.8

51.8

Age, range (months)

1.9–180.0

2.3–156

Bodyweight, mean (kg)

21.3

22.7

Bodyweight, range (kg)

3.5–53.3

2.8–70.0

Male, n (%)

143 (51.4)

67 (57.3)

Female, n (%)

135 (48.6)

50 (42.7)

Coat length, n (%)

 Short

126 (45.3)

52 (44.4)

 Medium

123 (44.2)

56 (47.9)

 Long

29 (10.4)

9 (7.7)

Number of dogs in each country (%)

 France

130 (46.8)

52 (44.4)

 Germany

26 (9.4)

9 (7.7)

 Hungary

122 (43.9)

56 (47.9)

Sleeping location, n (%)

 Inside

75 (27.0)

27 (23.1)

 Outside

203 (73.0)

90 (76.9)

Presence of fleas or ticks, n (%)

 No

182 (65.5)

79 (67.5)

 Yes

96 (34.5)

38 (32.5)

  1. IP Investigational product; combination tablets of lotilaner + milbemycin oxime (MO), marketed as Credelio Plus (Elanco Animal Health, Greenfield, IN, USA); CP control product; combination tablets of afoxolaner + MO, marketed as Nexgard Spectra (Boehringer Ingelheim, Ingelheim am Rhein, Germany)